Nivolumab’s mechanism of action

Nivolumab (Nivolumab) is an immune checkpoint inhibitor. Its mechanism of action involves the inhibition of immune regulatory pathways, thereby enhancing the body's immune response to cancer cells.

In the human immune system, there is a mechanism called immune checkpoint, which is used to regulate the intensity and scope of immune responses to prevent overactive autoimmune responses. PD-1 (programmed death -1) is an important immune checkpoint protein that plays a key role in T cell activation. PD-1 binds to its ligand PD-L1 (programmed death ligand -1), inhibiting the activity of T cells, weakening the immune response, thereby preventing one's own tissues from being attacked by the immune system.

However, some tumor cells are able to utilize thePD-1/PD-L1 pathway to evade immune system attack and survive and proliferate. The mechanism of action of nivolumab is to break the immune escape of tumor cells from the immune system by blocking the combination of PD-1 and PD-L1, thereby activating the immune response of T cells and enhancing the ability to attack tumor cells.

Specifically, nivolumab binds to the PD-1 receptor and prevents the binding of PD-1 to PD-L1, thereby releasing the inhibitory effect on T cells. In this way, the activity of T cells is restored, able to recognize and attack tumor cells, prompting the immune system to resume its anti-tumor role.

The mechanism of action of nivolumab is different from traditional chemotherapy drugs. It is a targeted immunotherapy drug with a more precise and specific mode of action. Therefore, nivolumab is widely used in the treatment of various malignant tumors and has shown significant efficacy in clinical trials. However, as an immunomodulator, nivolumab may also cause some adverse reactions, such as immune-related rash, fatigue, digestive tract problems, etc., so careful monitoring and management are required during use.